Previous studies found that in a lung mouse cancer model, this regimen can foster CD8+ T cell infiltration and increase TLR4+ DCs in tumor tissues, and further increase tumor sensitivity to immune checkpoint therapy (176). This evidence concerns the gene CD8A and neoplasm.